Skip to main content
SleepCited

むずむず脚症候群

A

合計24,923名の参加者を対象とした65件の研究(メタアナリシス5件を含む)に基づく。65件中34件の研究で肯定的な効果が示されている。

<\/script>\n
`; }, get iframeSnippet() { const domain = 'sleepcited.com'; const params = 'ingredient\u003Diron\u0026condition\u003Drestless\u002Dleg\u002Dsyndrome'; return ``; }, get activeSnippet() { return this.method === 'script' ? this.scriptSnippet : this.iframeSnippet; }, copySnippet() { navigator.clipboard.writeText(this.activeSnippet).then(() => { this.copied = true; setTimeout(() => { this.copied = false; }, 2000); }); } }" @keydown.escape.window="open = false" @click.outside="open = false">

Embed This Widget

Style



      
      
    

Widget powered by . Free, no account required.

A

結論

Iron supplementation is well-supported by research for reducing restless leg syndrome symptoms, especially in people with confirmed iron deficiency.

  • 65 studies with nearly 25,000 participants — one of the most studied supplement-condition pairs
  • A 2025 meta-analysis confirmed the efficacy and safety of iron for RLS
  • Iron deficiency is a recognized major risk factor for restless leg syndrome
  • IV iron (ferric carboxymaltose) shows particularly strong results in clinical trials

Key Study Findings

review
[Restless leg syndrome. Diagnosis and treatment].
Dose: various vs: Placebo 効果: None None
case-control n=90
Restless Leg Syndrome and Association with Serum NT Pro-CNP.
Dose: None vs: Placebo 効果: NT pro-CNP significantly lower in RLS vs controls; sensitivity 80%, specificity 88.9%; serum iron lo None
Cohort Study n=58 Open-label
Efficacy and safety of intravenous iron in patients with restless legs syndrome with normal serum …
Dose: 1000 mg ferric carboxymaltose vs: Group A (ferritin <100) vs Group B (ferritin 100-300) Outcome: IRLS severity scale score change 効果: None None

対象集団: RLS patients with serum ferritin <300 µg/L

review
Restless Leg Syndrome and Pregnancy.
Dose: iron supplementation, folate, dopamine agonists (non-pharmacological and pharmacological) vs: Placebo 効果: None None
review
[Restless Legs Syndrome].
Dose: dopamine agonists, iron supplementation, alpha-2-delta ligands vs: Placebo 効果: None None

Key Statistics

173

研究数

36638

参加者数

Mixed

A

グレード

Referenced Papers

Revista de neurologia None 8 件の引用
Medicina clinica 2025 11 件の引用
Naunyn-Schmiedeberg's archives of … 2025 4 件の引用
Handbook of clinical … 2025
Southern medical journal 2025
Brain and nerve … 2025
Sleep medicine reviews 2024 6 件の引用
Tremor and other … 2023 32 件の引用
Tremor and other … 2023 22 件の引用
Sleep medicine clinics 2023 14 件の引用
Sleep 2023 8 件の引用
Continuum (Minneapolis, Minn.) 2023 2 件の引用
Australian journal of … 2023
European journal of … 2022 109 件の引用
Experimental neurology 2022 36 件の引用
Antioxidants (Basel, Switzerland) 2022 13 件の引用
MMW Fortschritte der … 2022 1 件の引用
Nature reviews. Disease … 2021 163 件の引用
Neurotherapeutics : the … 2021 162 件の引用
Sleep medicine clinics 2021 14 件の引用
Current neuropharmacology 2021 13 件の引用
Sleep medicine clinics 2021 11 件の引用
Sleep medicine clinics 2021 9 件の引用
The International journal … 2021 6 件の引用
Sleep medicine clinics 2021 5 件の引用
International journal of … 2020 34 件の引用
Sleep medicine clinics 2020 18 件の引用
Continuum (Minneapolis, Minn.) 2020 17 件の引用
La Revue de … 2020 3 件の引用
Der Nervenarzt 2020 2 件の引用
The lancet. Diabetes … 2020 2 件の引用
The Neuroscientist : … 2019 120 件の引用
Current neurology and … 2019 68 件の引用
The Cochrane database … 2019 62 件の引用
Sleep medicine reviews 2019 47 件の引用
Advances in pharmacology … 2019 27 件の引用
Advances in pharmacology … 2019 20 件の引用
Drugs & aging 2019 14 件の引用
Advances in pharmacology … 2019 5 件の引用
Advances in pharmacology … 2019 3 件の引用
Advances in pharmacology … 2019 2 件の引用
The Lancet. Neurology 2018 202 件の引用
International review of … 2018 24 件の引用
Sleep medicine clinics 2018 21 件の引用
Revue neurologique 2018 11 件の引用
Pediatric annals 2018 5 件の引用
Missouri medicine 2018
Sleep medicine 2017 95 件の引用
FP essentials 2017 11 件の引用
Clinical medicine (London, … 2016 44 件の引用
Cytotechnology 2016 18 件の引用
Acta dermatovenerologica Croatica … 2016 6 件の引用
Wiener medizinische Wochenschrift … 2016 2 件の引用
Biometals : an … 2016
Sleep medicine clinics 2015 158 件の引用
Sleep medicine reviews 2015 38 件の引用
Sleep medicine clinics 2015 29 件の引用
Critical care clinics 2015 28 件の引用
Movement disorders : … 2015
Parkinsonism & related … 2014 78 件の引用
Handbook of clinical … 2014 52 件の引用
Nephro-urology monthly 2014 43 件の引用
The Journal of … 2014 7 件の引用
The Cochrane database … 2012 31 件の引用
Expert opinion on … 2012 6 件の引用
American family physician 2012
Indian journal of … 2011 75 件の引用
Handbook of clinical … 2011 8 件の引用
Nature reviews. Neurology 2010 293 件の引用
Current opinion in … 2010
Journal of internal … 2009 125 件の引用
Brain and nerve … 2009
The Israel Medical … 2008 61 件の引用
Acta medica portuguesa 2008
American family physician 2008
The Nurse practitioner 2008
American journal of … 2007 61 件の引用
The British journal … 2006 29 件の引用
American journal of … 2006 23 件の引用
Sleep medicine 2006 8 件の引用
The Lancet. Neurology 2005 215 件の引用
Progress in neurobiology 2005 47 件の引用
Current neurology and … 2005 15 件の引用
Neurologic clinics 2005 13 件の引用
Primary care 2005 2 件の引用
Current opinion in … 2005
Neurology 2004 386 件の引用
Annals of neurology 2004 183 件の引用
Sleep medicine reviews 2001 48 件の引用
The Journal of … 2001 7 件の引用
Sleep medicine reviews 1999 31 件の引用
Mayo Clinic proceedings 1997 30 件の引用
The American Journal … 1996 1 件の引用
Mayo Clinic proceedings 1990 68 件の引用
Canadian Medical Association … 1967

Dosage & Usage

mg = milligrams · mcg = micrograms (1,000× smaller) · IU = International Units

一般的な使用量

rls:
65 mg elemental iron if ferritin <75
general:
18 mg/day (women)

上限量: 45 mg/day

研究で検討された用量

用量 期間 効果 N
various -- Positive --
None -- Positive 90
1000 mg ferric carboxymaltose -- Positive 58
iron supplementation, folate, dopamine agonists (non-pharmacological and pharmacological) -- Positive --
dopamine agonists, iron supplementation, alpha-2-delta ligands -- Positive --
None -- Neutral --
None -- Mixed --
None -- Positive --

推奨摂取タイミング: On an empty stomach with vitamin C; take in the morning, not before bed

Safety & Side Effects

報告されている副作用

  • Constipation
  • Nausea
  • Stomach pain
  • Dark stools
  • Iron overload risk (hemochromatosis)

既知の相互作用

  • Antacids and PPIs — reduce iron absorption
  • Levothyroxine — iron reduces thyroid medication absorption
  • Antibiotics (tetracyclines, fluoroquinolones) — mutual absorption reduction
  • Calcium supplements — take separately by 2 hours

耐容上限摂取量: 45 mg/day

サプリメントの摂取を開始する前に、必ず医療専門家にご相談ください。

Frequently Asked Questions

Does 鉄 help with むずむず脚症候群?
Based on 173 studies with 36,638 participants, there is strong evidence from multiple clinical trials that 鉄 may support むずむず脚症候群 management. Our evidence grade is A (Strong Evidence).
How much 鉄 should I take for むずむず脚症候群?
Studies have used various dosages. A commonly studied range is 65 mg elemental iron if ferritin <75. Always consult your healthcare provider before starting any supplement regimen.
Are there side effects of 鉄?
Reported side effects may include Constipation, Nausea, Stomach pain, Dark stools. Most side effects are mild and dose-dependent. Consult your doctor if you experience any adverse reactions.
How strong is the evidence for 鉄 and むずむず脚症候群?
We rate the evidence as Grade A (Strong Evidence). This rating is based on 173 peer-reviewed studies with 36,638 total participants. The overall direction of effect is mixed.

Related Evidence

に関する他の成分: むずむず脚症候群

FDAに関する免責事項: これらの記述は米国食品医薬品局(FDA)による評価を受けていません。本ウェブサイトの製品および情報は、疾病の診断、治療、治癒、または予防を目的としたものではありません。表示されているエビデンスグレードは、公開された査読済み研究の分析に基づいており、医療上の助言を構成するものではありません。サプリメントの摂取を開始する前に、必ず医療専門家にご相談ください。